{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T11:47:05Z","timestamp":1784116025125,"version":"3.55.0"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"vor","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Formosan Medical Association"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.jfma.2025.11.008","type":"journal-article","created":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:57:03Z","timestamp":1762595823000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Prevalence of seropositive occult hepatitis B virus infection among patients received chemotherapy in Taiwan: A retrospective study"],"prefix":"10.1016","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6860-1051","authenticated-orcid":false,"given":"Pei-Yuan","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chih-Wen","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya-Huei","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wan-Yu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsu-Heng","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.jfma.2025.11.008_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL clinical practice guidelines on the management of hepatitis B virus infection","volume":"83","author":"Cornberg","year":"2025","journal-title":"J Hepatol"},{"issue":"8","key":"10.1016\/j.jfma.2025.11.008_bib3","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1111\/liv.15959","article-title":"Survey of hepatitis B virus infection status after 35 years of universal vaccination implementation in Taiwan","volume":"44","author":"Chang","year":"2024","journal-title":"Liver Int"},{"issue":"2","key":"10.1016\/j.jfma.2025.11.008_bib4","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.jhep.2019.03.034","article-title":"Update of the statements on biology and clinical impact of occult hepatitis B virus infection","volume":"71","author":"Raimondo","year":"2019","journal-title":"J Hepatol"},{"issue":"10","key":"10.1016\/j.jfma.2025.11.008_bib5","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1016\/S2468-1253(22)00201-1","article-title":"Prevalence of occult hepatitis B virus infection in adults: a systematic review and meta-analysis","volume":"7","author":"Im","year":"2022","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.008_bib6","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1111\/jvh.13660","article-title":"Global prevalence of occult hepatitis B: a systematic review and meta\u2010analysis","volume":"29","author":"Ji","year":"2022","journal-title":"J Viral Hepat"},{"issue":"39","key":"10.1016\/j.jfma.2025.11.008_bib7","doi-asserted-by":"crossref","first-page":"8720","DOI":"10.3748\/wjg.v22.i39.8720","article-title":"Update on occult hepatitis B virus infection","volume":"22","author":"Makvandi","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"7","key":"10.1016\/j.jfma.2025.11.008_bib8","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1111\/jvh.13928","article-title":"Occult hepatitis B virus infection and current perspectives on global WHO 2030 eradication","volume":"31","author":"Saravanan","year":"2024","journal-title":"J Viral Hepat"},{"issue":"5\u20136","key":"10.1016\/j.jfma.2025.11.008_bib9","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1053\/j.seminoncol.2024.08.001","article-title":"Hepatitis B virus reactivation in cancer patients receiving chemotherapy\u2014a systematic review and meta-analysis","volume":"51","author":"Deepan","year":"2024","journal-title":"Semin Oncol"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.008_bib10","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s12072-019-09966-z","article-title":"Prediction and clinical implications of HBV reactivation in lymphoma patients with resolved HBV infection: focus on anti-HBs and anti-HBc antibody titers","volume":"13","author":"Nishida","year":"2019","journal-title":"Hepatol Int"},{"issue":"12","key":"10.1016\/j.jfma.2025.11.008_bib11","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1002\/phar.2340","article-title":"Hepatitis B virus reactivation: risk factors and current management strategies","volume":"39","author":"Smalls","year":"2019","journal-title":"Pharmacotherapy"},{"issue":"12","key":"10.1016\/j.jfma.2025.11.008_bib12","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1136\/gutjnl-2011-301281","article-title":"Occult hepatitis B infection in blood donors from South East Asia: molecular characterisation and potential mechanisms of occurrence","volume":"61","author":"Candotti","year":"2012","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.008_bib13","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/hep.27650","article-title":"Universal infant immunization and occult hepatitis B virus infection in children and adolescents: a population\u2010based study","volume":"61","author":"Hsu","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.008_bib14","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.jhep.2020.05.042","article-title":"Occult hepatitis B infection and hepatocellular carcinoma: epidemiology, virology, hepatocarcinogenesis and clinical significance","volume":"73","author":"Mak","year":"2020","journal-title":"J Hepatol"},{"issue":"12","key":"10.1016\/j.jfma.2025.11.008_bib15","doi-asserted-by":"crossref","first-page":"2917","DOI":"10.1002\/jmv.25867","article-title":"Prevalence of occult HBV infection in Western countries","volume":"92","author":"Pisaturo","year":"2020","journal-title":"J Med Virol"},{"issue":"7","key":"10.1016\/j.jfma.2025.11.008_bib16","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.3390\/v14071504","article-title":"Occult hepatitis B virus infection: an update","volume":"14","author":"Saitta","year":"2022","journal-title":"Viruses"},{"issue":"11","key":"10.1016\/j.jfma.2025.11.008_bib17","doi-asserted-by":"crossref","first-page":"4068","DOI":"10.1128\/JCM.40.11.4068-4071.2002","article-title":"Occult hepatitis B virus infection and clinical outcomes of patients with chronic hepatitis C","volume":"40","author":"Kao","year":"2002","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.jfma.2025.11.008_bib18","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1111\/jvh.12687","article-title":"Chronologic changes in serum hepatitis B virus DNA, genotypes, surface antigen mutants and reverse transcriptase mutants during 25\u2010year nationwide immunization in Taiwan","volume":"24","author":"Hsu","year":"2017","journal-title":"J Viral Hepat"},{"issue":"6","key":"10.1016\/j.jfma.2025.11.008_bib19","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.jfma.2023.10.018","article-title":"The seroepidemiology of isolated core antibody against hepatitis B among Taiwanese adults - a large hospital-based study","volume":"123","author":"Kuo","year":"2024","journal-title":"J Formos Med Assoc"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.008_bib20","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1053\/jhep.2001.25172","article-title":"Persistent hepatitis B virus infection in subjects without hepatitis B surface antigen: clinically significant or purely \u201coccult\u201d","volume":"34","author":"Br\u00e9chot","year":"2001","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.jfma.2025.11.008_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.jhep.2022.01.030","article-title":"Absence of chronicity in infants born to immunized mothers with occult HBV infection in Taiwan","volume":"77","author":"Lai","year":"2022","journal-title":"J Hepatol"},{"issue":"11","key":"10.1016\/j.jfma.2025.11.008_bib22","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1111\/jgh.16725","article-title":"Rituximab carries high risks of hepatitis B virus reactivation in hematologic and rheumatic patients with chronic or resolved hepatitis B","volume":"39","author":"Hou","year":"2024","journal-title":"J Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.jfma.2025.11.008_bib23","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1053\/j.gastro.2024.11.008","article-title":"Spotlight: prevention and treatment of hepatitis B virus reactivation in at-risk individuals","volume":"168","author":"Ali","year":"2025","journal-title":"Gastroenterology"},{"issue":"5","key":"10.1016\/j.jfma.2025.11.008_bib24","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1007\/s12072-021-10239-x","article-title":"APASL clinical practice guideline on hepatitis B reactivation related to the use of immunosuppressive therapy","volume":"15","author":"Lau","year":"2021","journal-title":"Hepatol Int"},{"issue":"4","key":"10.1016\/j.jfma.2025.11.008_bib25","first-page":"554","article-title":"High prevalence of hepatitis B virus infection in B-cell non-Hodgkin\u2019s lymphoma","volume":"91","author":"Marcucci","year":"2006","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jfma.2025.11.008_bib26","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1007\/s00277-008-0469-9","article-title":"High prevalence of occult hepatitis B virus infection in patients with B cell non-Hodgkin\u2019s lymphoma","volume":"87","author":"Chen","year":"2008","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jfma.2025.11.008_bib27","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1275800","article-title":"Hepatitis B virus and B-cell lymphoma: evidence, unmet need, clinical impact, and opportunities","volume":"13","author":"Rosenberg","year":"2023","journal-title":"Front Oncol"},{"issue":"12","key":"10.1016\/j.jfma.2025.11.008_bib28","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1080\/10428194.2021.1948034","article-title":"Role of quantitative hepatitis B surface antibodies in preventing hepatitis B virus-related hepatitis in patients treated with rituximab","volume":"62","author":"Pei","year":"2021","journal-title":"Leuk Lymphoma"}],"container-title":["Journal of the Formosan Medical Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005972?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0929664625005972?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T09:57:06Z","timestamp":1762595826000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0929664625005972"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":27,"alternative-id":["S0929664625005972"],"URL":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.008","relation":{},"ISSN":["0929-6646"],"issn-type":[{"value":"0929-6646","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Prevalence of seropositive occult hepatitis B virus infection among patients received chemotherapy in Taiwan: A retrospective study","name":"articletitle","label":"Article Title"},{"value":"Journal of the Formosan Medical Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jfma.2025.11.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025, Formosan Medical Association. Published by Elsevier Taiwan LLC. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}